Table 2.
MetS status | Frequency of MV‐PA | Number of People | Number of MACEs | Follow‐Up (Person‐Years) | Incidence Rate (/1000 Person‐Years) | Unadjusted Model | Multivariable Model | ||
---|---|---|---|---|---|---|---|---|---|
IRR (95% CI) | P Value | Adjusted IRR (95% CI) | P Value | ||||||
MetS‐free | 0 d/wk | 1 840 026 | 17 237 | 7 981 115 | 2.16 | Reference | Reference | ||
1–2 d/wk | 1 531 152 | 8953 | 6 878 662 | 1.30 | 0.60 (0.59–0.62) | <0.001 | 0.84 (0.82–0.87) | <0.001 | |
3–4 d/wk | 756 270 | 5226 | 3 367 586 | 1.55 | 0.72 (0.70–0.74) | <0.001 | 0.80 (0.77–0.82) | <0.001 | |
≥5 d/wk | 420 090 | 4027 | 1 825 140 | 2.21 | 1.02 (0.99–1.06) | 0.222 | 0.84 (0.81–0.86) | <0.001 | |
MetS‐recovery | 0 d/wk | 145 047 | 3222 | 610 909 | 5.27 | 2.44 (2.35–2.54) | <0.001 | 1.40 (1.35–1.46) | <0.001 |
1–2 d/wk | 104 911 | 1423 | 468 051 | 3.04 | 1.41 (1.33–1.49) | <0.001 | 1.24 (1.17–1.31) | <0.001 | |
3–4 d/wk | 59 716 | 910 | 262 636 | 3.46 | 1.60 (1.50–1.71) | <0.001 | 1.17 (1.09–1.25) | <0.001 | |
≥5 d/wk | 38 639 | 772 | 163 687 | 4.72 | 2.18 (2.03–2.35) | <0.001 | 1.18 (1.09–1.26) | <0.001 | |
MetS‐developed | 0 d/wk | 156 540 | 4347 | 634 581 | 6.85 | 3.17 (3.07–3.28) | <0.001 | 1.47 (1.43–1.53) | <0.001 |
1–2 d/wk | 101 511 | 1840 | 436 850 | 4.21 | 1.95 (1.86–2.05) | <0.001 | 1.41 (1.34–1.48) | <0.001 | |
3–4 d/wk | 54 830 | 1084 | 231 489 | 4.68 | 2.17 (2.04–2.31) | <0.001 | 1.22 (1.14–1.3) | <0.001 | |
≥5 d/wk | 35 282 | 922 | 143 535 | 6.42 | 2.97 (2.78–3.18) | <0.001 | 1.24 (1.16–1.33) | <0.001 | |
MetS‐chronic | 0 d/wk | 406 137 | 15 625 | 1 624 863 | 9.62 | 4.45 (4.36–4.55) | <0.001 | 1.60 (1.56–1.64) | <0.001 |
1–2 d/wk | 225 524 | 6096 | 965 660 | 6.31 | 2.92 (2.84–3.01) | <0.001 | 1.60 (1.55–1.65) | <0.001 | |
3–4 d/wk | 136 733 | 3867 | 572 284 | 6.76 | 3.13 (3.02–3.24) | <0.001 | 1.37 (1.32–1.42) | <0.001 | |
≥5 d/wk | 95 669 | 3219 | 384 603 | 8.37 | 3.88 (3.73–4.02) | <0.001 | 1.30 (1.25–1.35) | <0.001 |
Multivariable model was adjusted for baseline age, sex, estimated glomerular filtration rate (continuous, mL/min per 1.73 m2), alanine aminotransferase (continuous, IU/mL), aspartate aminotransferase (continuous, IU/mL), hemoglobin (continuous, g/dL), low‐income status (the lowest quartile in the nation), body mass index (continuous, kg/m2), Charlson Comorbidity Index score, and place of residence (urban or rural). IRR indicates incidence rate ratio; MACE, major adverse cardiovascular events; MetS, metabolic syndrome; and MV‐PA, moderate‐to‐vigorous physical activity.